Sonnet Biotherapeutics Holdings Inc (SONN)

10:59 AM

Sonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumours - Clinical Trials Arena

10:59 AM

08:37 AM

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire

08:37 AM

08:35 AM

Sonnet BioTherapeutics CEO to Present at Webull Healthcare Investment Webinar - StockTitan

08:35 AM

02:12 AM

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - Defense World

02:12 AM

Jan 21, 2025

Sonnet BioTherapeutics begins trial combining SON-1010, trabectedin - MSN

Jan 21, 2025

Jan 21, 2025

Sonnet BioTherapeutics Expands Phase 1 Study for SON-1010 - TipRanks

Jan 21, 2025

Jan 21, 2025

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to - GlobeNewswire

Jan 21, 2025

Jan 21, 2025

Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today - MSN

Jan 21, 2025

Jan 03, 2025

Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga

Jan 03, 2025

Dec 23, 2024

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - GlobeNewswire

Dec 23, 2024

Dec 19, 2024

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Corporate UpdateOn December 17, 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, released it - Defense World

Dec 19, 2024

Dec 17, 2024

Insights into Sonnet BioTherapeutics Q4 Earnings - Benzinga

Dec 17, 2024

Dec 17, 2024

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Dec 17, 2024

Dec 17, 2024

Sonnet BioTherapeutics Slashes Operating Costs 37% in FY2024, Advances Cancer Drug Pipeline - StockTitan

Dec 17, 2024

Dec 13, 2024

Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga

Dec 13, 2024

Dec 12, 2024

Sonnet BioTherapeutics (NASDAQ: SONN) Announces $3.9 Million Registered Direct Offering and Private PlacementPrinceton, New Jersey, December 9, 2024 – Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company focusing on targeted i - Defense World

Dec 12, 2024

Dec 11, 2024

Sonnet BioTherapeutics (NASDAQ: SONN) Reports Positive Safety Data in SON-1010 Monotherapy Dose Escalation Trial - Defense World

Dec 11, 2024

Dec 10, 2024

Sonnet BioTherapeutics reports progress in cancer trial By Investing.com - Investing.com Nigeria

Dec 10, 2024

Dec 09, 2024

Sonnet BioTherapeutics reports progress in cancer trial - Investing.com India

Dec 09, 2024

Dec 09, 2024

Sonnet BioTherapeutics Announces $3.9 Million Registered - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Sonnet BioTherapeutics Secures $3.9M Strategic Financing Deal Through Mixed Securities Offering - StockTitan

Dec 09, 2024

Dec 09, 2024

Sonnet BioTherapeutics Announces Topline Safety Data - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Sonnet Bio's Cancer Drug Shows Promise: 48% Disease Control, One Patient's Tumor Shrinks 45% in Phase 1 Trial - StockTitan

Dec 09, 2024

Dec 05, 2024

Sonnet BioTherapeutics reports advances in cancer treatment drug By Investing.com - Investing.com Canada

Dec 05, 2024

Dec 04, 2024

Sonnet BioTherapeutics reports advances in cancer treatment drug - Investing.com India

Dec 04, 2024

Dec 04, 2024

Sonnet BioTherapeutics Announces Publication Detailing the - GlobeNewswire

Dec 04, 2024

Dec 04, 2024

Sonnet BioTherapeutics Unveils Breakthrough Cancer Drug Delivery System in Major Publication - StockTitan

Dec 04, 2024

Dec 02, 2024

Sonnet BioTherapeutics Holdings (STU:H3D) Financial Strengt - GuruFocus.com

Dec 02, 2024

Dec 02, 2024

Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail

Dec 02, 2024

Dec 01, 2024

Sonnet BioTherapeutics’ $5 Million Common Stock Offering - Global Legal Chronicle

Dec 01, 2024

Nov 23, 2024

Sonnet BioTherapeutics Holdings (STU:H3D) Change In Receiva - GuruFocus.com

Nov 23, 2024

Nov 12, 2024

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World

Nov 08, 2024

Nov 08, 2024

Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology

Nov 08, 2024

Nov 07, 2024

Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia

Nov 07, 2024

Nov 07, 2024

SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia

Nov 07, 2024

Nov 07, 2024

Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz

Nov 07, 2024

Nov 06, 2024

Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire

Nov 06, 2024

Nov 06, 2024

Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India

Nov 06, 2024

Nov 06, 2024

Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK

Nov 06, 2024

Nov 06, 2024

Sonnet BioTherapeutics Raises $5M in Stock Offering with Warrant Coverage | SONN Stock News - StockTitan

Nov 06, 2024

Nov 06, 2024

Sonnet BioTherapeutics secures patent for cancer drug candidates - Investing.com India

Nov 06, 2024

Nov 06, 2024

U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn

Nov 06, 2024

Nov 06, 2024

Sonnet BioTherapeutics Secures Patent for Cancer Drugs - TipRanks

Nov 06, 2024

Nov 06, 2024

Sonnet BioTherapeutics Announces Issuance of U.S. Patent - GlobeNewswire

Nov 06, 2024

Nov 06, 2024

Sonnet BioTherapeutics Secures Key Patent for Novel Cancer Immunotherapy Drugs | SONN Stock News - StockTitan

Nov 06, 2024

Oct 30, 2024

Sonnet stock tumbles 22% in wake of proposed offering filing - MSN

Oct 30, 2024